A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.

@article{Jansen2011ARP,
  title={A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.},
  author={Jan-Peter Jansen and Daniel Lorch and John P Langan and Ben Lasko and Kai Hermanns and Christi S Kleoudis and Jerry W Snidow and Amy A Pierce and John I Wurzelmann and Eric R. Mortensen},
  journal={The journal of pain : official journal of the American Pain Society},
  year={2011},
  volume={12 2},
  pages={185-93}
}
UNLABELLED Gastrointestinal (GI) side effects are common with opioid medication, and constipation affects ∼40% of patients. Such symptoms considerably impair patients' quality of life. Alvimopan is an orally administered, systemically available, peripherally acting mu-opioid receptor (PAM-OR) antagonist approved in the US for short-term, in-hospital management of postoperative ileus in patients undergoing bowel resection. This double-blind, placebo-controlled trial was conducted as part of a… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

Similar Papers

Loading similar papers…